Why the study?
Do modified commercial assay kits improve the sensitivity and early detection of hepatitis A antibodies following vaccination?
Do modified commercial assay kits improve the sensitivity and early detection of hepatitis A antibodies following vaccination?
Answers are grounded in this paper and cite their sources.
Modifying commercial hepatitis A antibody assays increases sensitivity 5- to 20-fold, allowing earlier detection post-vaccination.
Two commercial assay kits for detecting antibody to hepatitis A virus (anti-HAV) have been modified in order to increase their sensitivity. These modifications are made by less dilution of the test serum, in the case of Abbott HAVAB-M assay, or by an increase in the volumetric ratio of the test serum to the labeled anti-HAV in the case of the Abbott HAVAB assay. These modifications result in 5- to 20-fold increases in test sensitivity and enable the detection of anti-HAV at 2-3 weeks following vaccination. The earlier detection of anti-HAV is important to vaccine development in assuring the presence of antibody levels in travelers sooner after vaccination.
No takes yet. Share an insight, caveat, or question.
Miller et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: